Efficacy of Venetoclax-Based Therapy Followed By Allogeneic Transplantation in Newly Diagnosed and Relapsed/Refractory AML Patients
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-205250
Abstract: Introduction: Despite recent advances, the only curative approach for most acute myeloid leukemia (AML) patients remains allogeneic hematopoietic cell transplant (HCT). Results of HCT are superior when performed in complete remission (CR), and the prognosis… read more here.
Keywords: therapy; ven based; aml; group ... See more keywords
Optimal Therapy for Secondary Acute Myeloid Leukemia after Prior Hypomethylating Therapy
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-206258
Abstract: Background: Patients (pts) with secondary acute myeloid leukemia (sAML) emerging from myelodysplastic syndrome (AML-MR) with extensive prior hypomethylating agent (HMA) exposure remain a high unmet need with significantly worse survival (4.2 months) and complete remission… read more here.
Keywords: therapy; ven based; secondary acute; saml ... See more keywords
Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-208736
Abstract: Background: Venetoclax (Ven), a BCL2 inhibitor, has shown promising responses in multiple myeloma (MM) patients with t(11;14) and/or BCL2 expression. However, consistent benefit in clinical trials remain elusive. This report evaluates the efficacy and safety… read more here.
Keywords: multiple myeloma; treatment; initiation; ven based ... See more keywords
Venetoclax-based salvage therapy achieves high remission rates after 7+3 or low-dose cytarabine
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-8190
Abstract: Introduction: In the Brazilian public health system (SUS), salvage chemotherapy for fit patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) after standard 7+3 induction (7 days of cytarabine plus 3 days of an anthracycline) is… read more here.
Keywords: therapy; ven based; salvage; cytarabine ... See more keywords